rF1V vaccine with CpG 1018
/ Dynavax, US Department of Defense, Sanofi
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
May 23, 2024
Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
(clinicaltrials.gov)
- P2 | N=200 | Completed | Sponsor: Dynavax Technologies Corporation | Active, not recruiting ➔ Completed
Trial completion
October 03, 2023
Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
(clinicaltrials.gov)
- P2 | N=200 | Active, not recruiting | Sponsor: Dynavax Technologies Corporation | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2024 ➔ Apr 2024 | Trial primary completion date: Feb 2023 ➔ Nov 2023
Enrollment closed • Trial completion date • Trial primary completion date
August 18, 2022
Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
(clinicaltrials.gov)
- P2 | N=200 | Recruiting | Sponsor: Dynavax Technologies Corporation
New P2 trial
1 to 3
Of
3
Go to page
1